NasdaqCM - Nasdaq Real Time Price USD

Regulus Therapeutics Inc. (RGLS)

2.3200

+0.3100

+(15.42%)

At close: April 22 at 4:00:01 PM EDT

2.3400

+0.02

+(0.86%)

After hours: April 22 at 6:09:42 PM EDT

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]

Insider Monkey 4 days ago

RGLS
+15.42%
^RUT
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9th at 11:32 a.m. ET.

PR Newswire 20 days ago

RGLS
+15.42%
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks

Amid recent market fluctuations and economic uncertainties, investors are seeking opportunities that can weather the storm. Penny stocks, a term that might seem outdated, continue to hold potential for those willing to explore beyond the mainstream. These stocks often represent smaller or newer companies and can offer growth prospects at lower price points when backed by strong financials. In this article, we explore three promising penny stocks that stand out as potential hidden gems in...

Simply Wall St. 22 days ago

RGLS
+15.42%
DIBS
Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.3% and

PREMIUM
MT Newswires 26 days ago

PFE

WBA

RGLS
+15.42%
Top Midday Gainers

23andMe (ME) shares rose sharply amid heavy trading Thursday after a court authorized the company to

PREMIUM
MT Newswires 26 days ago

RGLS
+15.42%
ME
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment of ADPKD.

PR Newswire 26 days ago

RGLS
+15.42%
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity […]

Insider Monkey last month

RGLS
+15.42%
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. last month

RGLS
+15.42%
Regulus: Q4 Earnings Snapshot

SAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 20 cents.

Associated Press Finance last month

RGLS
+15.42%
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update.

PR Newswire last month

RGLS
+15.42%
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11th at 3:40 p.m. ET.

PR Newswire last month

RGLS
+15.42%
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against the other cheap stocks insiders are buying recently. Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks […]

Insider Monkey last month

RGLS
+15.42%
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 2:40 p.m. ET.

PR Newswire 2 months ago

RGLS
+15.42%
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00

Insiders who bought US$82.3k worth of Regulus Therapeutics Inc.'s ( NASDAQ:RGLS ) stock at an average buy price of...

Simply Wall St. 2 months ago

RGLS
+15.42%
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data

Regulus plans to initiate its Phase 3 trial later this year.

GuruFocus.com 2 months ago

RGLS
+15.42%
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline results from an interim analysis of the fourth cohort of its Phase 1b Multiple Ascending Dose (MAD) study of farabursen (RGLS8429) for the treatment of ADPKD and an overview on its recent successfu

PR Newswire 2 months ago

RGLS
+15.42%
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Regulus Therapeutics' stock price might be vulnerable...

Simply Wall St. 4 months ago

RGLS
+15.42%
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences:

PR Newswire 4 months ago

RGLS
+15.42%
Regulus: Q3 Earnings Snapshot

SAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $14.1 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 21 cents.

Associated Press Finance 5 months ago

RGLS
+15.42%
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2024.

PR Newswire 5 months ago

RGLS
+15.42%

Performance Overview

Return	RGLS	S&P 500 (^GSPC)
YTD	+46.84%	-10.10%
1-Year	+5.45%	+5.53%
3-Year	+0.87%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regulus Therapeutics Inc. (RGLS)

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks

Sector Update: Health Care Stocks Advance Late Afternoon

Top Midday Gainers

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?

Regulus: Q4 Earnings Snapshot

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00

Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus: Q3 Earnings Snapshot

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Performance Overview